Live
FierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatmentFierceBiotechCRO Fortrea launches AI-powered solution to improve trial efficiencyEndpoints NewsARPA-H selects three teams in $100M effort to repair and regrow ailing jointsBioPharma DiveGilead continues M&A surge with $3.1B deal for ADC specialist TubulisEndpoints NewsTerns sold to Merck for 13% lower than pharma's initial offer because of clinical dataEndpoints NewsNovo launches high-dose Wegovy in the US; Evotec pressured to list its US unitBioWorldEmory University synthesizes new prostaglandin EP2 receptor antagonistsBioWorldChengdu Kanghong Pharmaceutical patents new lipoprotein(a)-lowering agentsBioWorldHoliday notice
BioWorld Apr 7, 2026

Emory University synthesizes new prostaglandin EP2 receptor antagonists

Emory University synthesizes new prostaglandin EP2 receptor antagonists

Original
Body unavailable. Use the original source.

Directory

59 All